Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunotherapy for Eyelid Viral Papilloma
NCT06720467Phase 2Completed
- Sponsor
- Zagazig University
- Start
- Jun 2024
- Primary completion
- Mar 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of candida albicans antigen in viral wart, sponsored by Zagazig University. Primary endpoint: Complete Response up to 12 weeks. Started Jun 2024; status: completed.
02
Drugs
candida albicans antigen
03
Conditions
viral wart
Beyond the preview
Go deeper on NCT06720467.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06720467.